Navamedic ASA receives approval for conditional reimbursement for Mysimba® in Finland

Oslo, 7 September 2021 – Navamedic ASA (OSE: NAVA) receives approval for conditional reimbursement for Mysimba® in Finland from 1 November 2021. The company expects accelerated growth of Mysimba® in the Finnish market following the reimbursement, further fueled by Navamedic’s successful patient support program planned for launch in Finland in 2022.

Mysimba® is the first obesity treatment of its kind, combining both an oral medicin with a digital and custom-made patient support program to maximise patients’ success in treatment. Mysimba® reduces hunger and cravings, and provides control over food intake, while the patient support program provides help in lifestyle and behavioural change for patients throughout the treatment period.

“We are pleased to announce that we have received approval for conditional reimbursement for Mysimba in Finland. Navamedic is looking forward to expanding the availability of this unique medicine to the Finnish population,” says Kathrine Gamborg Andreassen, CEO of Navamedic ASA, and continues.

“Mysimba is one of the fastest growing products in our portfolio, displaying sales growth of 89% in the first half of 2021 compared to the same period last year. We have strong traction in both Norway, where we already have conditional reimbursement, and in Sweden, where we have seen impressive results from our our patient support program. Now we are looking forward to accelerate our growth of Mysimba in the Finnish market, further fueled by strong support from local key opinion leaders.”

According to the World Health Organization, around 13% of the world’s population suffer from obesity, defined as abnormal or excessive fat accumulation that presents a risk to health, with a Body Mass Index (BMI) above 30. Obesity is a contributing risk factor for diseases such as cardiovascular diseases, diabetes and some cancers. According to Navamedic’s estimates, around 900 000 people in Finland are obese.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic

Mobile: +47 951 78 680

E-mail: [email protected]

Lars Hjarrand, CFO, Navamedic

Mobile: +47 917 62 842

E-mail: [email protected]

Navamedic ASA is a Nordic pharma company and reliable provider of high-quality products, delivered to hospitals and through pharmacies, meeting the specific needs of patients and consumers by leveraging its highly scalable market access platform, leading category competence and local knowledge. Navamedic is present in all the Nordic countries, the Baltics and Benelux, with sales representation in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (ticker: NAVA). For more information, please visit www.navamedic.com

This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.